Seoul National University · Medicine
Professor Gi Jeong Cheon's research lab specializes in nuclear medicine and molecular imaging, with a focus on improving cancer diagnosis, prognosis, and treatment personalization. The lab investigates the clinical utility of advanced imaging techniques such as 18F-FDG PET/CT and MRI to predict treatment response in sarcomas and gynecological cancers. A key research direction involves using metabolic and anatomical imaging parameters—particularly SUVmax and tumor volume changes—to identify high-risk patients and guide individualized therapy. The lab also explores the application of bioimpedance analysis (BIA) for accurate body composition assessment in pediatric populations.
Figures are computed from collected data and may differ slightly.
Although the %BF was not interchangeable with DXA, MF-BIA8 (InBody 720; Biospace) could be used to measure body composition of children and adolescents in the clinical field because of its high precision.
Response to neoadjuvant chemotherapy is a significant prognostic factor for osteosarcoma; however, this information can be determined only after surgical resection. If we could predict histologic response before surgery, it might be helpful for the planning of surgeries and tailoring of treatment. We evaluated the usefulness of <sup>18</sup>F-FDG PET for this purpose. <b>Methods:</b> A total of 70 consecutive patients with a high-grade osteosarcoma treated at our institute were prospectively enr
Patients with uterine cervical cancer and a high SUVmax primary lesion, PLN, or para-aortic LN are at higher risk of adverse events or death.
Open papers in the app to read, cite, and organize with AI.
